Laryngeal squamous cell carcinoma · line 1 · Pembrolizumab monotherapy (HNSCC R/M, 1L; PD-L1 CPS ≥20)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-PEMBRO-MONO-HNSCC-1L |
| ID | IND-LARYNGEAL-RM-1L-PEMBRO-MONO-CPS-HIGH |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | DIS-LARYNGEAL |
| Sources | SRC-KEYNOTE-048-BURTNESS-2019 SRC-NCCN-HNSCC-2025 |
Notes
STUB pending Clinical Co-Lead sign-off (CHARTER §6.1). Mirrors IND-HNSCC-RM-1L-PEMBRO-MONO-CPS-HIGH field-for-field. Reuses REG-PEMBRO-MONO-HNSCC-1L and DRUG-PEMBROLIZUMAB unchanged — no new Regimen or Drug authored.
Used By
Algorithms
ALGO-LARYNGEAL-1L- ALGO-LARYNGEAL-1L